{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 33 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'electronic data capture (eDC) system. The amount of blood taken from the patient concerned', 'will be increased due to this additional sampling.', '5.2.4', 'Electrocardiogram', 'The 12-lead ECGs will be recorded as scheduled in the flowchart. The investigator or a', 'designee will evaluate whether the ECG is normal or abnormal and whether it is clinically', 'relevant, if abnormal. ECGs may be repeated for quality reasons and the repeated recording', 'used for analysis.', 'Additional ECGs may be recorded for safety reasons. Dated and signed printouts of ECG', \"with findings should be documented in patient's medical record.\", 'Clinically relevant abnormal findings will be reported either as baseline condition (if', 'identified at the screening visit) or otherwise as adverse events as described in Section 5.2.6', 'and will be followed up and/or treated as medically appropriate.', '5.2.5', 'Other safety parameters', 'Safety parameters to be assessed during the work cycle ergometry and 6 minute walk test are', 'described in Appendix 10.1.', '5.2.6', 'Assessment of adverse events', '5.2.6.1', 'Definitions of AEs', 'Adverse event', 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical', 'investigation subject administered a medicinal product and which does not necessarily have', 'to have a causal relationship with this treatment.', 'An AE can therefore be any unfavourable and unintended sign (including an abnormal', 'laboratory finding), symptom, or disease temporally associated with the use of a medicinal', 'product, whether or not considered related to the medicinal product.', 'Adverse reaction', 'An adverse reaction (ADR) is defined as a response to a medicinal product which is noxious', 'and unintended. Response in this context means that a causal relationship between a', 'medicinal product and an adverse event is at least a reasonable possibility. Adverse reactions', 'may arise from use of the product within or outside the terms of the marketing authorisation', 'or from occupational exposure. Conditions of use outside the marketing authorization include', 'off-label use, overdose, misuse, abuse and medication errors.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 34 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Serious adverse event', 'A serious adverse event is defined as any AE which', '-', 'results in death,', '-', 'is life-threatening,', '-', 'requires in-patient hospitalization, or', '-', 'prolongation of existing hospitalisation,', '- results in persistent or significant disability or incapacity, or', '-', 'is a congenital anomaly/birth defect', 'Life-threatening in this context refers to a reaction in which the patient was at risk of death at', 'the time of the reaction; it does not refer to a reaction that hypothetically might have caused', 'death if more severe.', 'Medical and scientific judgement should be exercised in deciding whether other situations', 'should be considered serious reactions, such as important medical events that might not be', 'immediately life threatening or result in death or hospitalisation but might jeopardise the', 'patient or might require intervention to prevent one of the other outcomes listed above.', 'Examples of such events are intensive treatment in an emergency room or at home for', 'allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation or', 'development of dependency or abuse. Any suspected transmission via a medicinal product of', 'an infectious agent is also considered a serious adverse reaction.', 'Adverse events of special interest (AESIs)', 'The term AESI relates to any specific AE that has been identified at the project level as being', 'of particular concern for prospective safety monitoring and safety assessment within this trial,', 'e.g. the potential for AEs based on knowledge from other compounds in the same class.', 'The following are considered as AESIs:', 'Gastrointestinal perforation', 'Hepatic injury', 'A hepatic injury is defined by the following alterations of hepatic laboratory parameters:', 'an elevation of AST and/or ALT >3 fold upper limit of normal (ULN) combined with', 'an elevation of total bilirubin >2 fold ULN measured in the same blood draw sample,', 'and/or', 'aminotransferase (ALT, and/or AST) elevations >10 fold ULN', 'These lab findings constitute a hepatic injury alert and the patients showing these lab', 'abnormalities need to be followed up according to the \"DILI checklist\" provided in the ISF or', 'eCRF.', 'In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy,', 'unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results', '(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}